ArticleAesthetic surgery journal. Open forum2026
An Innovative Injection Technique for Treating Edematous Fibrosclerotic Panniculopathy (Cellulite): A Prospective Multicenter Clinical Investigation.
Article in Aesthetic surgery journal. Open forum, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Edematous fibrosclerotic panniculopathy (EFP) affects ∼80% to 98% of postpubertal women and has a significant impact on quality of life. Its unclear etiopathology and the multifactorial origin pose a significant challenge for its clinical management. This study aimed to evaluate the efficacy and the safety of a commercially available mixture of hyaluronic acid and amino acids in an alkaline solution. A prospective multicenter clinical trial was carried out on 46 women with EFP Stage I to early Stage IV. The improvement of cellulite severity was evaluated by the modified Clinician-Reported Photonumeric Cellulite Severity Scale (CR-PCSS) and the modified Patient-Reported PCSS (PR-PCSS) before the first (T1), the second (T2), and the third injection (T3) and after 3 (T4) and 6 (T5) months of treatment. The psychological impact of cellulite was measured using the Objectified Body Consciousness (OBC) scale. The PR-PCSS revealed that 95.3% of participants reported an improvement in their appearance. These positive outcomes remained consistent up to 6 months following the initial treatment. Similarly, the CR-PCSS showed that as early as 2 weeks after the first treatment, 76.7% of participants demonstrated objective improvement based on the Global Aesthetic Improvement Scale. These improvements also remained stable for up to 6 months. Self-esteem (OBC scale) was improved. No major adverse events were reported; minor bruising occurred as expected because of injections. Sunekos Cell 15 is a possibly effective and well-tolerated treatment for cellulite, particularly in cases with pronounced fibrosis, potentially offering a minimally invasive therapeutic option. Level of Evidence: 4 (Therapeutic) For image description, please refer to the figure legend and surrounding text.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.